Laila C Roisman
Overview
Explore the profile of Laila C Roisman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roisman L, Mann S, Basel A, Marei R, Krayim B, Kornev G, et al.
Clin Lung Cancer
. 2025 Mar;
PMID: 40064573
Introduction: Despite recent advances in immunotherapy combinations for extensive-stage small cell lung cancer (ES-SCLC), rapid disease progression following chemotherapy discontinuation remains a significant challenge. While the addition of pembrolizumab to...
2.
Kian W, Krayim B, Giles B, Elkiaan N, Idris A, Fink D, et al.
Front Oncol
. 2024 Nov;
14:1286116.
PMID: 39605892
Background: Over the past decade, progress in the diagnosis and treatment of Non-Small Cell Lung Cancer (NSCLC) has led to the identification of many targeted mutations. This has enhanced PFS...
3.
Kian W, Remilah A, Shatat C, Spector M, Roisman L, Ryvo L
Front Med (Lausanne)
. 2024 Oct;
11:1461127.
PMID: 39421875
Introduction: Vitamin C (L-ascorbic acid) plays a vital role in human physiology, serving as both an antioxidant and a cofactor in enzymatic reactions. High-dose intravenous Vitamin C can achieve significantly...
4.
Shemesh R, Laufer-Geva S, Gorzalczany Y, Anoze A, Sagi-Eisenberg R, Peled N, et al.
Sci Rep
. 2023 Dec;
13(1):21544.
PMID: 38057448
Mast cells (MCs) are immune cells that play roles in both normal and abnormal processes. They have been linked to tumor progression in several types of cancer, including non-small cell...
5.
Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer
Roisman L, Kian W, Anoze A, Fuchs V, Spector M, Steiner R, et al.
NPJ Precis Oncol
. 2023 Nov;
7(1):125.
PMID: 37990050
Personalized medicine has revolutionized approaches to treatment in the field of lung cancer by enabling therapies to be specific to each patient. However, physicians encounter an immense number of challenges...
6.
Prelaj A, Ganzinelli M, Trovo F, Roisman L, Pedrocchi A, Kosta S, et al.
Clin Lung Cancer
. 2023 Mar;
24(4):381-387.
PMID: 36959048
Although immunotherapy (IO) has changed the paradigm for the treatment of patients with advanced non-small cell lung cancers (aNSCLC), only around 30% to 50% of treated patients experience a long-term...
7.
Peled N, Roisman L, Levison E, Dudnik J, Chernomordikov E, Heching N, et al.
Int J Radiat Oncol Biol Phys
. 2023 Mar;
117(1):105-114.
PMID: 36925073
Purpose: The treatment for unresectable, locally advanced stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiation therapy (CRT) followed by consolidation durvalumab. This study aimed to evaluate the benefit...
8.
Kian W, Krayim B, Alsana H, Giles B, Purim O, Alguayn W, et al.
Front Oncol
. 2023 Mar;
13:1124949.
PMID: 36923435
Lung cancer is the most common cancer-related cause of death worldwide, most of which are non-small cell lung cancers (NSCLC). Epidermal growth factor receptor (EGFR) mutations are common drivers of...
9.
Iraqi M, Bolel P, Sarkar R, Bhattacharya B, Abu Ahmad M, Edri A, et al.
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430528
Lung cancer cells in the tumor microenvironment facilitate immune evasion that leads to failure of conventional chemotherapies, despite provisionally decided on the genetic diagnosis of patients in a clinical setup....
10.
Kian W, Christopoulos P, Remilah A, Levison E, Dudnik E, Shalata W, et al.
Front Oncol
. 2022 Oct;
12:1010311.
PMID: 36203432
Background: Non-small cell lung cancer (NSCLC) harboring exon 20 insertions (ex20ins) is relatively resistant to the existing tyrosine kinase inhibitors (TKIs). Mobocertinib is a novel TKI that selectively targets ex20ins...